Post-Merger, Biotechs, Pharmas Need Strategy to Sync R&D
By Marie Powers
Thursday, June 21, 2012
BOSTON Since the BIO International Convention was last held in Boston in 2007, the number of publicly traded biotech companies has declined by 35 percent, from 394 to 255, David Thomas, BIO's director of industry research and analysis, told conference attendees Wednesday morning.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.